Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001193125-22-037129
Filing Date
2022-02-11
Accepted
2022-02-11 16:24:59
Documents
2
Group Members
BLACKSTONE CLARUS DE L.L.C.BLACKSTONE CLARUS GP L.L.C.BLACKSTONE CLARUS GP L.P.BLACKSTONE CLARUS III L.L.C.BLACKSTONE GROUP MANAGEMENT L.L.C.BLACKSTONE HOLDINGS I L.P.BLACKSTONE HOLDINGS I/II GP L.L.CBLACKSTONE INC.CLARUS DE II, L.P.CLARUS DEFINED EXIT I,

Document Format Files

Seq Description Document Type Size
1 SC 13G d260730dsc13g.htm SC 13G 351154
2 EX-99.1 d260730dex991.htm EX-99.1 26547
  Complete submission text file 0001193125-22-037129.txt   379964
Mailing Address C/O THE BLACKSTONE GROUP 345 PARK AVENUE NEW YORK NY 10154
Business Address C/O THE BLACKSTONE GROUP 345 PARK AVENUE NEW YORK NY 10154 212-583-5000
Blackstone Holdings II L.P. (Filed by) CIK: 0001484870 (see all company filings)

EIN.: 260288604
Type: SC 13G

Mailing Address 201 E. JEFFERSON ST., SUITE 110B LOUISVILLE KY 40202
Business Address 201 E. JEFFERSON ST., SUITE 110B LOUISVILLE KY 40202 502-569-1059
Talaris Therapeutics, Inc. (Subject) CIK: 0001827506 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-92543 | Film No.: 22621460
SIC: 2836 Biological Products, (No Diagnostic Substances)